Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CRHBP | P24387 | 2/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30062655 | 1.00 | MAPT (0.59) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL15982275 | 1.00 | MAPT (0.59) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL15982303 | 1.00 | MAPT (0.59) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL11933408 | 1.00 | MAPT (0.59) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL13840327 | 1.00 | MAPT (0.59) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL16253986 | 1.00 | MAPT (0.59) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL15033875 | 0.94 | LMNA (0.65) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL11905 | 0.93 | MAPT (0.53) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL14410337 | 0.92 | LMNA (0.52) | MAPTLMNAHTTBLMKDM4E | |
| SCHEMBL14176972 | 0.86 | MAPT (0.46) | MAPTLMNAHTTBLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220393174-A1 | CROWN ETHERS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-12-08 | — | — | US | disclosed |
| US-20220193249-A1 | Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-O-) Units In A Ring | POLYTHERICS LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-20210226251-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING CROWN ETHER BASED COMPOUNDS | ENEVATE CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-10654873-B2 | Cytotoxic agents and conjugates thereof | POLYTHERICS LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190328893-A1 | Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-0-) Units In A Ring | POLYTHERICS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190202839-A1 | Novel Cytotoxic Agents And Conjugates Thereof | ABZENA (CAMBRIDGE) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-9786941-B2 | Metal ionophores in PEM membranes | GM Global Technology Operations LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-9077038-B2 | Lithium ion batteries | GM Global Technology Operations LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9077038-B2 | Lithium ion batteries | GM Global Technology Operations LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150105239-A1 | CROWN ETHER CONTAINING PEM ELECTRODE | GM GLOBAL TECH OPERATIONS INC (US) | 2015-04-16 | — | — | US | disclosed |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010106078-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| EP-0882717-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654873-B2 | Cytotoxic agents and conjugates thereof | CD2BP2, DDB1, DCLRE1A | MAPT 4353/4885LMNA 3151/4885HTT 4547/4885 |
| US-20120142937-A1 | METHOD FOR COUPLING HALOGEN-SUBSTITUTED AROMATIC COMPOUNDS WITH ORGANIC COMPOUNDS COMPRISING TRIALKYLSILYL-SUBSTITUTED HETEROATOMS | TYR, ALK, TTL | MAPT 1726/4885LMNA 3396/4885HTT 198/4885 |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | CYP2C8, CYP2C18, CYP4B1 | MAPT 2644/4885LMNA 2396/4885HTT 1050/4885 |
| US-20190202839-A1 | Novel Cytotoxic Agents And Conjugates Thereof | CD2BP2, DDB1, DCLRE1A | MAPT 4584/4885LMNA 3092/4885HTT 4711/4885 |
| US-20190328893-A1 | Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-0-) Units In A Ring | BCR, CD2BP2, LANCL1 | MAPT 843/4885LMNA 3160/4885HTT 794/4885 |
| US-20220193249-A1 | Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-O-) Units In A Ring | BCR, CD2BP2, LANCL1 | MAPT 941/4885LMNA 3400/4885HTT 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.